Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Gajewski

Showing results (11-20 of 236) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
On the TRAIL toward death receptor-based cancer therapeuticsThomas F Gajewski
Seminars in Oncology|August 31, 2015
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor MicroenvironmentThomas F Gajewski
Pigment Cell & Melanoma Research|July 9, 2010
Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapyThomas F Gajewski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironmentThomas F Gajewski
The New England Journal of Medicine|May 24, 2018
Fast Forward - Neoadjuvant Cancer ImmunotherapyThomas F Gajewski
Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancerJustin Kline, Thomas F Gajewski
Nature Reviews. Cancer|January 13, 2018
Impact of oncogenic pathways on evasion of antitumour immune responsesStefani Spranger, Thomas F Gajewski
Current Protocols in Cytometry|September 5, 2008
Diagnosis and treatment of mycoplasma-contaminated cell culturesHelena Harlin, Thomas F Gajewski
Cellular Immunology|September 28, 2007
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cellsYuanyuan Zha, Thomas F Gajewski
Science Immunology|July 22, 2022
CXCL9 and CXCL10 bring the heat to tumorsRobin Reschke, Thomas F Gajewski
Pageof 24

Showing results (11-20 of 236) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2007
On the TRAIL toward death receptor-based cancer therapeuticsThomas F Gajewski
Seminars in Oncology|August 31, 2015
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor MicroenvironmentThomas F Gajewski
Pigment Cell & Melanoma Research|July 9, 2010
Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapyThomas F Gajewski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironmentThomas F Gajewski
The New England Journal of Medicine|May 24, 2018
Fast Forward - Neoadjuvant Cancer ImmunotherapyThomas F Gajewski
Current Opinion in Investigational Drugs (London, England : 2000)|December 15, 2010
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancerJustin Kline, Thomas F Gajewski
Nature Reviews. Cancer|January 13, 2018
Impact of oncogenic pathways on evasion of antitumour immune responsesStefani Spranger, Thomas F Gajewski
Current Protocols in Cytometry|September 5, 2008
Diagnosis and treatment of mycoplasma-contaminated cell culturesHelena Harlin, Thomas F Gajewski
Cellular Immunology|September 28, 2007
An adenoviral vector encoding dominant negative Cbl lowers the threshold for T cell activation in post-thymic T cellsYuanyuan Zha, Thomas F Gajewski
Science Immunology|July 22, 2022
CXCL9 and CXCL10 bring the heat to tumorsRobin Reschke, Thomas F Gajewski
Pageof 24